ALK and neoplasm: While the use of tyrosine kinase inhibitors (TKIs) represents a significant advancement in the therapeutic management of these tumors, providing more specific and effective treatment options, resistance in tumor cells may occur during the use of TKIs, which is partially explained by the occurrence of mutations in the ALK domain that halts the drug interaction with the oncogene [19,22,23,24,25,26,27,28].